(Q43047392)

English

High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial

scientific article published in August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Eveline J Boucher

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sylvie Jacquelinet

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Valérie Canva

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Bruno Turlin

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Christian Jacquelinet

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ronald Colimon

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yves Deugnier

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Dominique Guyader

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Pierre Brissot

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

255-261

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

21 January 2018

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0676.2003.00836.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1034/J.1600-0676.2003.00836.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43047392&oldid=1978752494"